Allergan, Restasis Buyers Can't Agree On MDL Venue
All parties involved in antitrust suits claiming Allergan Inc. delayed the launch of generic versions of its dry-eye medication Restasis — in part by transferring patents to a Native American tribe...To view the full article, register now.
Already a subscriber? Click here to view full article